BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Relypsa, Inc. Raises $49.7 Million of $80 Million Funding Round


8/13/2012 8:01:05 AM

Silicon Valley / San Jose Business Journal by Jon Xavier, Web Producer

Relypsa Inc., a clinical stage biopharmaceutical company working on treatments for hyperkalemia in patients with diabetes, cronic kidney disease, and heart failure, said Friday in a filing with the SEC that it had raised $49.7 million of a $80 million Series C round.

The Santa Clara-based pharmaceutical company offered equity to secure the funding. All told, this brings the company's funding to $183 million. Relypsa's previous investors include 5AM Ventures, New Leaf Venture Partners, The Sprout Group, Delphi Ventures, CMEA Ventures, Mediphase Venture Partners and OrbiMed Advisors.

Relypsa is currently in Phase 2 of clinical trials for its RKY5016 high-capacity cation binder, which is being investigated to treat the high levels of potassium in the blood that sometimes occur as a side effect of diabetes and kidney disease. At extreme levels, potassium can cause potentially fatal heart attacks. Relypsa's treatment has already successfully completed five clinical trials.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES